[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse HRH3

Summary
SymbolHRH3
Namehistamine receptor H3
Aliases GPCR97; HH3R; H3R; Histamine H3 receptor
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Multi-pass membrane protein.
Domain PF00001 7 transmembrane receptor (rhodopsin family)
Function

The H3 subclass of histamine receptors could mediate the histamine signals in CNS and peripheral nervous system. Signals through the inhibition of adenylate cyclase and displays high constitutive activity (spontaneous activity in the absence of agonist). Agonist stimulation of isoform 3 neither modified adenylate cyclase activity nor induced intracellular calcium mobilization.

> Gene Ontology
 
Biological Process GO:0001505 regulation of neurotransmitter levels
GO:0001820 serotonin secretion
GO:0006820 anion transport
GO:0006835 dicarboxylic acid transport
GO:0006836 neurotransmitter transport
GO:0006837 serotonin transport
GO:0007187 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger
GO:0007188 adenylate cyclase-modulating G-protein coupled receptor signaling pathway
GO:0007193 adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway
GO:0007197 adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway
GO:0007200 phospholipase C-activating G-protein coupled receptor signaling pathway
GO:0007207 phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway
GO:0007213 G-protein coupled acetylcholine receptor signaling pathway
GO:0007269 neurotransmitter secretion
GO:0007271 synaptic transmission, cholinergic
GO:0014047 glutamate secretion
GO:0014048 regulation of glutamate secretion
GO:0014050 negative regulation of glutamate secretion
GO:0014061 regulation of norepinephrine secretion
GO:0014062 regulation of serotonin secretion
GO:0014063 negative regulation of serotonin secretion
GO:0015711 organic anion transport
GO:0015837 amine transport
GO:0015844 monoamine transport
GO:0015850 organic hydroxy compound transport
GO:0015874 norepinephrine transport
GO:0023061 signal release
GO:0043271 negative regulation of ion transport
GO:0044070 regulation of anion transport
GO:0046942 carboxylic acid transport
GO:0048243 norepinephrine secretion
GO:0050432 catecholamine secretion
GO:0050433 regulation of catecholamine secretion
GO:0050890 cognition
GO:0051048 negative regulation of secretion
GO:0051051 negative regulation of transport
GO:0051937 catecholamine transport
GO:0051952 regulation of amine transport
GO:0060359 response to ammonium ion
GO:0071242 cellular response to ammonium ion
GO:0095500 acetylcholine receptor signaling pathway
GO:0099531 presynaptic process involved in chemical synaptic transmission
GO:0099643 signal release from synapse
GO:1903531 negative regulation of secretion by cell
GO:1903792 negative regulation of anion transport
GO:1903831 signal transduction involved in cellular response to ammonium ion
GO:1905144 response to acetylcholine
GO:1905145 cellular response to acetylcholine
Molecular Function GO:0004969 histamine receptor activity
GO:0008227 G-protein coupled amine receptor activity
GO:0015464 acetylcholine receptor activity
GO:0016907 G-protein coupled acetylcholine receptor activity
GO:0030594 neurotransmitter receptor activity
GO:0099528 G-protein coupled neurotransmitter receptor activity
Cellular Component GO:0098793 presynapse
> KEGG and Reactome Pathway
 
KEGG hsa04080 Neuroactive ligand-receptor interaction
Reactome R-HSA-375280: Amine ligand-binding receptors
R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-418594: G alpha (i) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-390650: Histamine receptors
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
Summary
SymbolHRH3
Namehistamine receptor H3
Aliases GPCR97; HH3R; H3R; Histamine H3 receptor
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between HRH3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolHRH3
Namehistamine receptor H3
Aliases GPCR97; HH3R; H3R; Histamine H3 receptor
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of HRH3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolHRH3
Namehistamine receptor H3
Aliases GPCR97; HH3R; H3R; Histamine H3 receptor
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of HRH3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2170.426
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.6180.322
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0690.876
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.030.972
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.6030.625
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.6890.622
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4801
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.8770.0156
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of HRH3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 414250250.222
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolHRH3
Namehistamine receptor H3
Aliases GPCR97; HH3R; H3R; Histamine H3 receptor
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HRH3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolHRH3
Namehistamine receptor H3
Aliases GPCR97; HH3R; H3R; Histamine H3 receptor
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HRH3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HRH3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolHRH3
Namehistamine receptor H3
Aliases GPCR97; HH3R; H3R; Histamine H3 receptor
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HRH3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolHRH3
Namehistamine receptor H3
Aliases GPCR97; HH3R; H3R; Histamine H3 receptor
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of HRH3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolHRH3
Namehistamine receptor H3
Aliases GPCR97; HH3R; H3R; Histamine H3 receptor
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between HRH3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolHRH3
Namehistamine receptor H3
Aliases GPCR97; HH3R; H3R; Histamine H3 receptor
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting HRH3 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting HRH3.
ID Name Drug Type Targets #Targets
DB00370MirtazapineSmall MoleculeADRA1A, ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2C, ADRB1, ADRB2, DRD1 ......23
DB05080OBE101Small MoleculeHRH1, HRH32
DB05381HistamineSmall MoleculeHRH1, HRH2, HRH3, HRH4, SLC18A25
DB06698BetahistineSmall MoleculeHRH1, HRH32
DB11642PitolisantSmall MoleculeHRH3, KCNH22